Welcome to NanoViricide's Investor Relations section.
NanoViricides, Inc. is a leading company in the application of nanomedicine technologies to the complex issues of viral diseases. The nanoviricide® technology permits direct attacks at multiple points on a virus particle. It is believed that such actions lead to the virus particle becoming ineffective at infecting cells. Antibodies in contrast attack a virus particle at only a maximum of two attachment points per antibody.
We have been aggressively expanding our portfolio of virus targets and drug candidates every year since our inception in May, 2005.
"PENICILLIN" FOR VIRUSES
Eradicating Diseases Caused by Viruses Using 21st Century Technology
Presented by: Eugene Seymour, MD, MPH
Chief Executive Officer
June - 2016
June 26, 2017 - NanoViricides' Poster Novel Nanoviricides Highly Effective Against Varicella Zoster Virus in Cell Culture to be Presented Today at the 2017 Annual Meeting of American Society of Virology
April 26, 2017 - NanoViricides CEO Dr. Seymour to Present an Update on the Company at The Planet Microcap Showcase - 2017 in Las Vegas; Company Says it is Close to Declaring a Clinical Candidate for the Treatment of Shingles
- 04-15-2014 NanoViricides won the IAIR AWARD
- NanoViricides won the IAIR AWARD as Best North American Company for Leadership in the Nanomedicine Sector.
- 02-20-2014Dr. Anil R. Diwan Recognized as "Researcher of the year".
- NanoViricides, Inc. President Dr. Anil R. Diwan Recognized as "Researcher of the Year" by BusinessNewHaven, a Connecticut Area Business Journal.
1 Controls Drive,
Shelton, CT 06484